DAAN J.A. CROMMELIN is Professor at the Department of Pharmaceutics at Utrecht University. Until December 2011 he was scientific director of the Dutch Top Institute Pharma in Leiden. He is adjunct professor at the Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah. Dr. Crommelin is co-founder of OctoPlus, a Leiden based company specialized in the development of pharmaceutical product formulations and advanced drug delivery systems. He published over 335 articles and has held leadership positions at the International Pharmaceutical Federation (FIP) and the European Federation for Pharmaceutical Sciences (EUFEPS).ROBERT D. SINDELAR is currently President, The Providence Health Care Research Institute, Vice President Research and Academic, Providence Health Care (part of the British Columbia public health care system), Professor Faculty of Pharmaceutical Sciences and Associate Dean Research Faculty of Medicine The University of British Columbia (UBC).  He served for 11 years as Dean and Professor, The UBC Faculty of Pharmaceutical Sciences following 19 years at the University of Mississippi where he held the positions of Professor and Chair of Medicinal Chemistry, School of Pharmacy and served as Interim Dean.  Dr. Sindelar’s expertise lies in medicinal chemistry, computer-aided drug discovery and design, pharmaceutical biotechnology, and creating opportunities to integrate innovation into the health care system. BERND MEIBOHM is Professor of Pharmaceutical Sciences and Associate Dean for Research and Graduate Programs at the University of Tennessee College of Pharmacy in Memphis. His area of expertise lies in clinical pharmacology and pharmacokinetic/pharmacodynamics correlations. Dr. Meibohm obtained his doctoral degree in Pharmaceutics from the Technical University Carolo-Wilhelmina, Braunschweig, Germany and received postdoctoral training at the University of Florida,Gainesville. Dr. Meibohm is a fellow of the American Association of Pharmaceutical Scientists and the American College of Clinical Pharmacology, and has published three textbooks, more than 90 peer-reviewed research articles and book chapters, 130 abstracts, and over 100 invited scientific presentations to national and international audiences.

• Molecular Biotechnology: From DNA sequence to therapeutic protein.- Biophysical and Biochemical Analysis of Recombinant Proteins.- Production and purification of Recombinant Proteins.- Formulation of Biotech Products, including Biopharmaceutical Considerations.- Pharmacokinetics and Pharmacodynamics of Peptide and Protein Therapeutics.- Immunogenicity of Therapeutic Proteins.- Monoclonal Antibodies: From Structure to Therapeutic Application.- Genomics, Other “Omics” Technologies, Personalized Medicine and Additional Biotechnology-Related Techniques.- Dispensing Biotechnology Products: Handling, Professional Education and Product Information.- Economic Considerations in Medical Biotechnology.- Regulatory Framework for Biosimilars.- Insulin.- Follicle-Stimulating Hormone.- Human Growth Hormone.- Recombinant Coagulation Factors And Thrombolytic Agents.- Recombinant Human Deoxyribonuclease I.- Monoclonal Antibodies in Cancer.- Hematopoietic Growth Factors: Focuson Erythropoiesis-Stimulating Agents.- Monoclonal Antibodies in Solid Organ Transplantation.- Interferons and Interleukins.- Vaccines.- Oligonucleotides.- Gene Therapy.- Stem Cell Technology.

DAAN J.A. CROMMELIN is Professor at the Department of Pharmaceutics at Utrecht University. Until December 2011 he was scientific director of the Dutch Top Institute Pharma in Leiden. He is adjunct professor at the Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah. Dr. Crommelin is co-founder of OctoPlus, a Leiden based company specialized in the development of pharmaceutical product formulations and advanced drug delivery systems. He published over 335 articles and has held leadership positions at the International Pharmaceutical Federation (FIP) and the European Federation for Pharmaceutical Sciences (EUFEPS).ROBERT D. SINDELAR is currently President, The Providence Health Care Research Institute, Vice President Research and Academic, Providence Health Care (part of the British Columbia public health care system), Professor Faculty of Pharmaceutical Sciences and Associate Dean Research Faculty of Medicine The University of British Columbia (UBC).  He served for 11 years as Dean and Professor, The UBC Faculty of Pharmaceutical Sciences following 19 years at the University of Mississippi where he held the positions of Professor and Chair of Medicinal Chemistry, School of Pharmacy and served as Interim Dean.  Dr. Sindelar’s expertise lies in medicinal chemistry, computer-aided drug discovery and design, pharmaceutical biotechnology, and creating opportunities to integrate innovation into the health care system. BERND MEIBOHM is Professor of Pharmaceutical Sciences and Associate Dean for Research and Graduate Programs at the University of Tennessee College of Pharmacy in Memphis. His area of expertise lies in clinical pharmacology and pharmacokinetic/pharmacodynamics correlations. Dr. Meibohm obtained his doctoral degree in Pharmaceutics from the Technical University Carolo-Wilhelmina, Braunschweig, Germany and received postdoctoral training at the University of Florida,Gainesville. Dr. Meibohm is a fellow of the American Association of Pharmaceutical Scientists and the American College of Clinical Pharmacology, and has published three textbooks, more than 90 peer-reviewed research articles and book chapters, 130 abstracts, and over 100 invited scientific presentations to national and international audiences.

• Molecular Biotechnology: From DNA sequence to therapeutic protein.- Biophysical and Biochemical Analysis of Recombinant Proteins.- Production and purification of Recombinant Proteins.- Formulation of Biotech Products, including Biopharmaceutical Considerations.- Pharmacokinetics and Pharmacodynamics of Peptide and Protein Therapeutics.- Immunogenicity of Therapeutic Proteins.- Monoclonal Antibodies: From Structure to Therapeutic Application.- Genomics, Other “Omics” Technologies, Personalized Medicine and Additional Biotechnology-Related Techniques.- Dispensing Biotechnology Products: Handling, Professional Education and Product Information.- Economic Considerations in Medical Biotechnology.- Regulatory Framework for Biosimilars.- Insulin.- Follicle-Stimulating Hormone.- Human Growth Hormone.- Recombinant Coagulation Factors And Thrombolytic Agents.- Recombinant Human Deoxyribonuclease I.- Monoclonal Antibodies in Cancer.- Hematopoietic Growth Factors: Focuson Erythropoiesis-Stimulating Agents.- Monoclonal Antibodies in Solid Organ Transplantation.- Interferons and Interleukins.- Vaccines.- Oligonucleotides.- Gene Therapy.- Stem Cell Technology.

DAAN J.A. CROMMELIN is Professor at the Department of Pharmaceutics at Utrecht University. Until December 2011 he was scientific director of the Dutch Top Institute Pharma in Leiden. He is adjunct professor at the Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah. Dr. Crommelin is co-founder of OctoPlus, a Leiden based company specialized in the development of pharmaceutical product formulations and advanced drug delivery systems. He published over 335 articles and has held leadership positions at the International Pharmaceutical Federation (FIP) and the European Federation for Pharmaceutical Sciences (EUFEPS).ROBERT D. SINDELAR is currently President, The Providence Health Care Research Institute, Vice President Research and Academic, Providence Health Care (part of the British Columbia public health care system), Professor Faculty of Pharmaceutical Sciences and Associate Dean Research Faculty of Medicine The University of British Columbia (UBC).  He served for 11 years as Dean and Professor, The UBC Faculty of Pharmaceutical Sciences following 19 years at the University of Mississippi where he held the positions of Professor and Chair of Medicinal Chemistry, School of Pharmacy and served as Interim Dean.  Dr. Sindelar’s expertise lies in medicinal chemistry, computer-aided drug discovery and design, pharmaceutical biotechnology, and creating opportunities to integrate innovation into the health care system. BERND MEIBOHM is Professor of Pharmaceutical Sciences and Associate Dean for Research and Graduate Programs at the University of Tennessee College of Pharmacy in Memphis. His area of expertise lies in clinical pharmacology and pharmacokinetic/pharmacodynamics correlations. Dr. Meibohm obtained his doctoral degree in Pharmaceutics from the Technical University Carolo-Wilhelmina, Braunschweig, Germany and received postdoctoral training at the University of Florida,Gainesville. Dr. Meibohm is a fellow of the American Association of Pharmaceutical Scientists and the American College of Clinical Pharmacology, and has published three textbooks, more than 90 peer-reviewed research articles and book chapters, 130 abstracts, and over 100 invited scientific presentations to national and international audiences.

• Molecular Biotechnology: From DNA sequence to therapeutic protein.- Biophysical and Biochemical Analysis of Recombinant Proteins.- Production and purification of Recombinant Proteins.- Formulation of Biotech Products, including Biopharmaceutical Considerations.- Pharmacokinetics and Pharmacodynamics of Peptide and Protein Therapeutics.- Immunogenicity of Therapeutic Proteins.- Monoclonal Antibodies: From Structure to Therapeutic Application.- Genomics, Other “Omics” Technologies, Personalized Medicine and Additional Biotechnology-Related Techniques.- Dispensing Biotechnology Products: Handling, Professional Education and Product Information.- Economic Considerations in Medical Biotechnology.- Regulatory Framework for Biosimilars.- Insulin.- Follicle-Stimulating Hormone.- Human Growth Hormone.- Recombinant Coagulation Factors And Thrombolytic Agents.- Recombinant Human Deoxyribonuclease I.- Monoclonal Antibodies in Cancer.- Hematopoietic Growth Factors: Focuson Erythropoiesis-Stimulating Agents.- Monoclonal Antibodies in Solid Organ Transplantation.- Interferons and Interleukins.- Vaccines.- Oligonucleotides.- Gene Therapy.- Stem Cell Technology.